Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) was the target of unusually large options trading on Friday. Stock investors acquired 41,629 call options on the stock. This is an increase of 98% compared to the typical daily volume of 20,996 call options.
Analyst Ratings Changes
A number of brokerages have recently issued reports on HZNP. TheStreet cut Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a report on Monday, May 8th. StockNews.com assumed coverage on shares of Horizon Therapeutics Public in a research report on Thursday. They issued a “buy” rating for the company. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $111.42.
Institutional Investors Weigh In On Horizon Therapeutics Public
Several hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. acquired a new position in shares of Horizon Therapeutics Public in the 4th quarter valued at about $460,920,000. Soros Fund Management LLC acquired a new position in Horizon Therapeutics Public in the fourth quarter valued at approximately $325,297,000. Marshall Wace LLP grew its holdings in shares of Horizon Therapeutics Public by 1,481.3% during the third quarter. Marshall Wace LLP now owns 2,506,329 shares of the biopharmaceutical company’s stock valued at $155,118,000 after purchasing an additional 2,347,834 shares during the last quarter. Norges Bank acquired a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth approximately $249,778,000. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Horizon Therapeutics Public by 36.6% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,000,000 shares of the biopharmaceutical company’s stock worth $796,600,000 after purchasing an additional 1,875,000 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.
Horizon Therapeutics Public Trading Up 1.2 %
Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last released its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 EPS for the quarter, missing the consensus estimate of $1.17 by ($0.34). The business had revenue of $832.10 million for the quarter, compared to analysts’ expectations of $897.06 million. Horizon Therapeutics Public had a net margin of 10.40% and a return on equity of 20.31%. The business’s quarterly revenue was down 6.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 earnings per share. Sell-side analysts forecast that Horizon Therapeutics Public will post 4.95 EPS for the current fiscal year.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
Featured Stories
- Get a free research report on Horizon Therapeutics Public from StockNews.com
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Wayfair: From Steep Decline to Recent Surge
- Five stocks we like better than Horizon Therapeutics Public
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.
